logo
'I was too fat for NHS cancer surgery appointment'

'I was too fat for NHS cancer surgery appointment'

BBC News01-04-2025
A woman diagnosed with inflammatory breast cancer has told the BBC the NHS said her Body Mass Index (BMI) was too high to discuss surgery.Rosemarie Winfield, 44, from Hailsham in East Sussex, was diagnosed in 2024 and is currently undergoing treatment. She had been referred to the Queen Victoria Hospital (QVH) in East Grinstead to discuss reconstruction options if she were to decide on a mastectomy but said she was "essentially... too fat for them even to speak to me".The hospital trust said it aimed to "treat every patient with respect and empathy" and was sorry Ms Winfield felt disappointed.
Ms Winfield, who has a BMI of 36, said: "My expectation was that QVH was going to talk to me about what the reconstruction options were."However, she said she was told "we can't see you because your BMI is too high... and obviously that was upsetting."Inflammatory breast cancer is a rare type of cancer, which blocks the lymph vessels in the breasts, causing them to become red and inflamed.It "can develop quickly" and "in general, the outlook for this type of cancer is worse than for other types of breast cancer", according to Cancer Research.Ms Winfield said: "It's quite a rare and serious type of cancer - there's a 50% chance I'll be here in five years."She said if patients were overweight "then help them to lose weight, give them that support if they want a reconstruction rather than just cut off options for people".
'This is a disgrace'
Ms Winfield received an apology after complaining to QVH but said: "Every patient should be treated with kindness and empathy within the NHS."They treated me like a subhuman based on an unscientific BMI number. This is a disgrace."
Louise Grimsdell, senior clinical nurse specialist at Breast Cancer Now, said: "Women with breast cancer need to be provided with clear information, and have all suitable options discussed with them."Some people may be advised not to have breast reconstruction, and this may be for a number of reasons, including having a high body mass index (BMI). "Women who are advised not to have reconstruction, or to have delayed reconstruction due to their BMI, should receive clear explanations about the reasons for this."
A spokesperson for QVH said: "We aim to treat every patient with respect and empathy and we are sorry that Ms Winfield felt disappointed."To undergo complex breast reconstruction at QVH, patients need to fulfil certain medical criteria, including being non-smokers and having a body mass index (BMI) below 35. "This is because post-operative complications increase dramatically for patients with a higher BMI, which can also compromise further cancer treatment such as chemo or radiotherapy."The hospital said a safer option would be to have mastectomy surgery, take time to recover, and then consider breast reconstruction as a delayed procedure. The hospital also said it offered a "prehabilitation programme" to help patients lose weight and improve fitness prior to elective surgery.It said it was investigating Miss Winfield's experience "fully" and had offered her an appointment to discuss her concerns with a breast reconstruction consultant, or, if she preferred, an urgent referral to another hospital for a second opinion.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Weight-loss jabs could help obese people control asthma, study suggests
Weight-loss jabs could help obese people control asthma, study suggests

Rhyl Journal

time22 minutes ago

  • Rhyl Journal

Weight-loss jabs could help obese people control asthma, study suggests

The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. 'Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. 'More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.'

Weight-loss jabs could help obese people control asthma, study suggests
Weight-loss jabs could help obese people control asthma, study suggests

Leader Live

time22 minutes ago

  • Leader Live

Weight-loss jabs could help obese people control asthma, study suggests

The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. 'Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. 'More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.'

Weight-loss jabs could help obese people control asthma, study suggests
Weight-loss jabs could help obese people control asthma, study suggests

North Wales Chronicle

time22 minutes ago

  • North Wales Chronicle

Weight-loss jabs could help obese people control asthma, study suggests

The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. 'Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. 'More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store